Metastatic cancer hcc
Conținutul
Duda's group is focused on studies of tumor interaction with its microenvironment, with the goal of identifying the cellular and molecular mechanisms of: 1 local tumor progression in liver cancers and metastatic tumor progression in other gastrointestinal cancers and in prostate and breast malignanciesand 2 treatment resistance in advanced cancers.
The ultimate goal is to identify and validate targets for combination therapy with radiation and immunotherapy in preclinical studies, and in parallel conduct studies of biomarkers of response in correlative clinical studies.
Cancerul Hepatic
He has been invited to present his results at over local, national and international meetings, including Grand Rounds, Plenary Metastatic cancer hcc and Metastatic cancer hcc Lectures. For his work, Dr. After graduation, he pursued postdoctoral training with Professor Rakesh K.
For more information, see full CV at: steele. Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.
Clin Cancer Res A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat Clin Transl Radiat Oncol ; Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Debate: Optimal treatment of localized HCC? - Ablation
Cancer Med Hepatology Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer PEACE : A study protocol. Endosc Ultrasound JAMA Oncol Cancer Res ; FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer NPJ Breast Cancer ; Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Sci Rep ; Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma. Sci Transl Med Enhancing cancer immunotherapy using antiangiogenics: opportunities metastatic cancer hcc challenges. Nat Rev Clin Oncol Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.
cancer Hepatocellular
NPJ Precis Oncol ; Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics ; Metastatic cancer hcc 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.
Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United European Gastroenterol J ; A cerebellar window for intravital imaging of normal and disease states in mice.
Vlad1, R. Moldovanu1, C. Lupaşcu1, G.
Nat Protoc ; Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? Anti-angiogenesis for cancer revisited: Is there a role metastatic cancer hcc combinations with immunotherapy? Angiogenesis A metastatic cancer hcc 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Oncologist Feasibility, phase I, and metastatic cancer hcc II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
